CYCN - Cyclerion's olinciguat data in sickle cell did not support clinical development

After announcing encouraging data from IW-6463 CNS translational pharmacology study, Cyclerion Therapeutics tanked ([[CYCN]] -48.0%) after it said that top-line results from its Phase 2 study of olinciguat, did not demonstrate adequate activity to support further internal clinical development.The Phase 2 STRONG-SCD study of 70 participants, was designed to evaluate safety, tolerability, and pharmacokinetics of olinciguat, compared to placebo, as well as to explore effects on daily symptoms and biomarkers of sickle cell disease, when dosed over a 12-week treatment period.

For further details see:

Cyclerion's olinciguat data in sickle cell did not support clinical development